Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer

BACKGROUND. Icrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR‐1 and ‐2), respectively. This open‐label, randomized phase II study evaluated their efficacy and safety in combination with capecitabine (CAP) in patients with previously treated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Vahdat, Linda T., Layman, Rachel, Yardley, Denise A., Gradishar, William, Salkeni, Mohamad A., Joy, Anil Abraham, Garcia, Agustin A., Ward, Patrick, Khatcheressian, James, Sparano, Joseph, Rodriguez, Gladys, Tang, Shande, Gao, Ling, Dalal, Rita P., Kauh, John, Miller, Kathy
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344637/
https://ncbi.nlm.nih.gov/pubmed/28220020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0265
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados